Abstract
The neurological and biochemical deficits in monkeys with unilateral ventromedial tegmental lesions of the brain stem were compared with those treated with MPTP. The effects of D1 an D2 dopamine agonists on parkinsonian-like symptoms were investigated in both non– human primate models. The stimulation of D2 dopamine receptors elicits a complete relief of tremor in monkeys with unilateral ventromedial tegmental lesions of the brain stem and a relief of parkinsonian-like symptomatology in MPTP-treated monkeys. The combined administration of bromocriptine with L-dopa produces an increased duration of the relief of tremor in monkeys with unilateral ventromedial tegmental lesions of the brain stem when compared with each drug alone. It is postulated that the presence of synaptic dopamine enhances the dopamine agonist activity of bromocriptine at the D2 dopamine receptors. Dopamine agonists which effectively stimulate dopamine autoreceptors and postsynaptic supersensitive, but not normosensitive dopamine receptors, effectively relieve tremor and do not produce severe abnormal involuntary movements in monkeys with unilateral ventromedial tegmental lesions of the brain stem. The therapeutic potential of selective dopamine agonists in treatment of Parkinson’s disease has to be further evaluated.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Arnt, J., Hyttel, J. and Perregaard, J. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur. J. Pharmacol. 133:137–145,1987
Elsworth, J.D., Deutch, A.Y., Redmond, D.E., Jr., Sladek, J.R., Jr. and Roth, R.H. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF Brain Res. 415:293299, 1987
Gershanik, O., Heikkila, R.E. and Duvoisin, R.C. Effects of dopamine depletion on rotational behavior to dopamine agonists. Brain Res. 261:358–360, 1983
Goldstein, M., Battista, A.F., Ohmoto, T., Anagnoste, B. and Fuxe, K. Tremor and involuntary movements in monkeys: Effect of L-Dopa and of a dopamine receptor stimulating agent. Science 179:816–817, 1973
Goldstein, M., Lieberman, A. and Meller, E. A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. Trends Pharmacol. Sci. 6:436–437, 1985
Goldstein, M., Fuxe, K., Meller, E., Seyfried, C. A., Agnati, L. and Mascagni, F.M. The characterization of the dopaminergic profile of EMD 23,448, an indoly 1–3-butylamine selective actions on presynaptic and supersensitive postsynaptic DA receptor populations. J. Neural Transm. 70:193–215, 1987
Hjorth, S., Carlsson, A., Wikstrom, H., Lindberg, P, Sanchez, D., Hacksell, U., Arvidsson, L.E., Svensson, U. and Nilsson, J.L.G. 3-PPP, a new centrally acting DA receptor agonists with selectivity for autoreceptors. Life Sci. 28:1225–1238, 1981
Koller, W.C., Fields, J.Z., Gordon, J.H. and Perlow, M.J. Evaluation of ciladopa hydrochloride as a potential anti-parkinson drug. Neuropharmacol. 25:973979, 1986
Martin, G.E., Williams, M., Pettibone, D.J., Yarbrough, G.G., Clineschmidt, B.V. and Jones, J.H. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propy 1–9-hydroxynaphthoxazine [(+)-PHNO]. J. Pharmacol. Exp. Ther. 230:569–576, 1984
Meller, E., Bohmaker, K., Namba, Y., Friedhoff, A.J. and Goldstein, M. Relationship between receptor occupancy and response at striatal dopamine receptors. Mol. Pharmacol. 31:592–5898, 1987
Poirier, L.J. and Sourkes, T.L. Influence of the substantia nigra on the catecholamine content of the striatum. Brain 88:181, 1965
Walters, J.R. Bergatrom, D.A., Carlson, J.H., Chase, T.N. and Braun, A.R. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 236:719–722, 1987
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Goldstein, M., Deutch, A.Y. (1988). The Therapeutic Potential of D1 and D2 Dopamine Agonists in Parkinson’S Disease. In: Hefti, F., Weiner, W.J. (eds) Progress in Parkinson Research. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0759-4_8
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0759-4_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8068-2
Online ISBN: 978-1-4613-0759-4
eBook Packages: Springer Book Archive